Gelsolin inhibits the proliferation and invasion of the 786-0 clear cell renal cell carcinoma cell line in vitro
- Authors:
- Published online on: September 10, 2015 https://doi.org/10.3892/mmr.2015.4313
- Pages: 6887-6894
Abstract
Introduction
Renal cell carcinoma (RCC) arises from the renal tubular epithelium and accounts for 2–3% of all adult malignancies in the USA (1). RCC varies widely from region to region, with the highest rates observed in North America and the Czech Republic (2) and it is the tenth most common type of cancer in Europe (3). RCC includes various different histologic subtypes that possess distinct biological behaviors and prognoses (4). Four types of RCC have been clinically characterized, with 85% of cases of adult RCC being clear cell RCC (ccRCC), while the other 15% are the papillary, chromophobe and oncocytic types (1). The incidence of ccRCC is steadily increasing by 2.5% per year, and >64,700 new cases and 13,500 mortalities were reported in 2012 (5). Since advanced ccRCC is highly resistant to chemotherapy and cytotoxic therapeutic agents, one-third of patients will experience recurrence following resection of the tumor (6). Furthermore, a quarter of patients present with locally invasive or metastatic RCC (7). Therefore, the factors involved in disease progression and metastasis provide molecular targets to facilitate the development of effective therapeutic strategies.
Gelsolin (GSN) is a widely distributed actin-binding protein, consisting of six domains (G1–G6), which regulates cytoskeletal turnover. GSN has two forms that are encoded by one gene on chromosome 9 in humans: Intracellular (cytoplasmic; cGSN) and extracellular (plasma; pGSN). cGSN is ubiquitously expressed in cells and tissues, and although there are various expression levels during cell differentiation and carcinogenesis pGSN is predominantly expressed within muscle cells (8). GSN mediates various cell functions, including cell motility, morphogenesis and actin cytoskeletal remodeling. The most extensively examined roles of GSN are its actin filament severing, capping, uncapping and nucleating activities (9). Furthermore, GSN appears to exert complex roles in tumor biology, with evidence supporting its involvement in tumor suppression and malignant progression. GSN is reported to be downregulated in certain types of tumor, including breast cancer (10) and renal clear cell carcinoma (11), indicating that depletion of GSN promotes oncogenesis. However, to the best of our knowledge, there is no evidence that GSN is involved in the proliferation and invasion of ccRCC. The aim of the current study was to investigate the effect of GSN on the proliferation and invasion of ccRCC by transfection of a GSN overexpression lentiviral vector, pLen0-DCE-RTP-gelsolin, into 786-0 ccRCC cell line cells in vitro.
Materials and methods
Cell lines and culture
The 786-0 ccRCC cell line and pack-aging cell line, 293T were purchased from the cell bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in RPMI-1640 (Gibco Life Technologies, Carlsbad, CA, USA) and Dulbecco's modified Eagle's medium (IBCO kit; Gibco Life Technologies) supplemented with 10% fetal bovine serum (Takara Biotechnology Co., Ltd., Dalian, China) and 1% penicillin-streptomycin (100 µg/ml; Invitrogen Life Technologies, Beijing, China) for 48 h at 37°C under an atmosphere of 5% CO2.
Construction of the plen0-DCE-RTP-gelsolin vector and lentivirus packaging
A specific primer was designed using Primer Premier 5.0 software (Shanghai Shenggong Biology Engineering Technology Service, Ltd., Shanghai, China) according to the nucleotide sequences of the human GSN gene, as reported in Genebank (http://www.ncbi.nlm.nih.gov/genbank/; reference sequence: NM_000177.4). The primer sequence for GSN was as follows: Forward, 5′-GGAATTCATGGCTCCGCACCGCCCC-3′; and reverse, 5′-CGGGATCCTCAGGCAGCCAGCTCAG-3′. The coding DNA sequence region of the GSN gene was amplified using a Madison polymerase chain reaction (PCR) kit (Promega Corporation, Madison, WI, USA) according to the manufacturer's instructions. The target DNA gene fragment was subcloned into the pLen0-DCE-RTP lentiviral vector (Baili Biotechnology Co., Ltd., Shanghai, China) to construct a GSN overexpression lentiviral vector (pLen0-DCE-RTP-gelsolin). The GSN was identified by PCR and DNA sequencing. PCR amplification was performed using the following reaction mixture: 1X PCR reaction buffer (50 mM KCl and 20 mM Tris-HCl, pH 8.4; Promega Corporation), primers (2.5 µM each), 3 mM MgCl2, 0.5 mM dNTPs, 0.4 µg template DNA, 1X Q solution and 5 Unit Taq polymerase (Takara Biotechnology Co., Ltd.). The final reaction volume was 50 µl. The amplification was performed under the following conditions: 94°C for 2 min, 98°C for 10 sec, 55°C for 30 sec, 68°C for 2.5 min and 30 cycles at 68°C for 5 min using a thermocycler (SimpliAmp™; Promega Corporation). The PCR products were separated on a 2% agarose gel (Lonza Group Ltd., Basel, Switzerland) using 25 and 50 bp molecular weight DNA markers (DL2000TM) and stained with ethidium bromide (Lonza Group Ltd.). The separated gene fragments were analyzed using a iCycler iQ™ Real Time PCR Detection and Image Collection system (Lonza Group Ltd.). The images were scanned using a Bio-Rad GelDoc 1000 Gel Documentation system (Bio-Rad Laboratories, Inc., Hercules, CA, USA). The PCR products were purified and sequenced by Gene Co., Ltd. (Beijing, China).
Exponential 293T cells were seeded in 10-cm cell culture dishes (2–2.5×106 cells/dish). The lentiviral vector packaging system (volume, 1,800 µl) was added to the cells at a density of 60–70%. After the supernatant was collected by centrifugation at 30 × g for 15 min at 4°C, the high-concentration lentiviral concentrate was used to infect the 293T cells. The ratio of positive cells (2×108 TU/ml) was detected by flow cytometry (FACS Calibur; BD Biosciences, San Jose, CA, USA) and the virus titer was detected using a double dilution assay.
Lentiviral transfection of the 786-0 ccRCC cells
Exponential 786-0 cells were seeded in 24-well culture plates (3–5×104 cells/well). The viral supernatant with plen0-DCE-RTP-gelsolin and green fluorescent protein (GFP) was added into the cells at a density of 70–80%. After 72 h, the transfection ratio was determined under a fluorescence microscope. The cells with a transfection ratio of >80% served as the target cells and were identified by western blot analysis.
There were three experimental groups, including the GSN overexpression group (786-0/GSN), the empty vector group (786-0/GFP) and a control group (786-0). All experiments were performed in triplicate.
MTT assay
The three experimental groups of cells were seeded in 96-well plates at 200 µl/well (1×105 cells/ml). Following culturing for 0, 12, 24, 36, 48, 60 or 72 h, 20 µl MTT (5 mg/ml) was added to the well. The optical density (OD) value of the cells was determined at a wavelength of 490 nm (GE Healthcare, Uppsala, Sweden).
Cell adhesion assay
Matrigel (Sigma-Aldrich, St. Louis, MO, USA) was added into 96-well plates (50 µg/well). The three groups of cells were resuspended in 0.1% bovine serum albumin (BSA) RPMI-1640 serum-free medium (Gibco Life Technologies) and added in to the wells with the Matrigel (2×104 cells/well). The 0.1% BSA-1640 serum-free medium served as the blank group. There were three repeated wells for each group. Following removal of the non-adherent cells by rinsing with RPMI-1640, the OD value of the cells in each well was determined at a wavelength of 570 nm using a Thermo Scientific Multiskan® Spectrum spectrophotometer (Bio-Tek Instruments, Inc., Winooski, VT, USA).
Transwell invasion assay
Transwell filters (Corning Incorporated, Corning, NY, USA) were coated with 3.9 µg/µl Matrigel (60–80 µl). The three groups of cells were resuspended in 100 µl serum-free RPMI-1640 medium and added into the upper compartment of the chambers. The cells migrating from the Matrigel into the pores of the inserted filter were fixed with 100% methanol (Sigma-Aldrich), and stained with hematoxylin (Sigma-Aldrich). The positive-stained cells were counted under three randomly selected visual fields at ×400 magnification with a fluorescence microscope (SMZ1000; Nikon Corporation, Tokyo, Japan).
ELISA
Three groups of cells were seeded in 96-well plates at 200 µl/well (1×105 cells/ml) and the supernatant was extracted by centrifugation at 30 × g for 15 min at 4°C. The expression levels of matrix metalloproteinase (MMP)2 and MMP9 were determined using ELISA kits (Human MMP-2/Human MMP-9 DuoSet ELISA; R&D Systems Europe, Ltd., Lille, France) according to the manufacturer's instructions.
Western blot analysis
Total protein was extracted from each of thee three groups of cells using lysis buffer containing 50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1 mM EDTA, supplemented with protease inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Protein (30 µg) was subjected to SDS-PAGE and transferred to nitrocellulose membranes (Sigma-Aldrich). Protein samples (30 µg) were separated by 10% SDS-PAGE (Bio-Rad Laboratories, Inc.) and transferred onto nitrocellulose membranes (Sigma-Aldrich) for 2 h at 4°C at 200 mA. The membranes were then blocked for 1 h at room temperature with 5% non-fat milk. Following electrophoresis of the membranes, the proteins were incubated with primary antibodies against monoclonal mouse anti-human MMP2 (cat. no. MAB-0244), monoclonal mouse anti-human MMP9 (cat. no. MAB-0245) (Cell Signaling Technology, Inc., Danvers, MA, USA), monoclonal mouse anti-human E-cadherin (clone: NCH-38; Dako, Carpinteria, CA, USA) and monoclonal mouse anti-human GSN (cat. no. SC-401005; Shengke Lusi Biotechnology Ltd., Shanghai, China) at 4°C (dilution, 1:800). The membranes were then incubated with horseradish peroxidase-conjugated antibodies (cat. no. PV6002; Zhongshan Goldenbridge Biotechnology, Beijing, China) for 30 min at 37°C (dilution, 1:800). The antigen-antibody reaction was visualized by enhanced chemiluminescence (Sigma-Aldrich) and GAPDH (cat. no. AB-82633, Abcam, Cambridge, UK) served as the internal reference.
Statistical analysis
The data were analyzed using SPSS Software version 11.5 (SPSS, Inc., Chicago, IL, USA). The data are presented as the mean ± standard deviation and the paired Samples t-test was conducted to investigate differences within the groups for the qualitative variables. P<0.05 was considered to indicate a statistically significant difference.
Results
Construction of the plen0-DCE-RTP-gelsolin vector and cell transfection
The plen0-DCE-RTP-gelsolin vector was constructed and identified by PCR and DNA sequencing. PCR analysis demonstrated that a single fragment was visible at ~15 kDa on 1% agarose gel (Fig. 1). In addition, DNA sequencing indicated that the recombinant plasmid contained the correct GSN gene fragment. The plen0-DCE-RTP-gelsolin vector (virus titer, 2.0×108 TU/ml) was transfected into the 786-0 ccRCC cells. Green fluorescence was apparent in the infected 786-0 cells, as observed under a fluorescence microscope, and indicated successful transfection (Fig. 2). Western blot analysis demonstrated that the expression level of GSN was markedly increased in the 786-0/GSN cells, when compared with the 786-0/GFP and 786-0 cells (Table II and Fig. 3).
Inhibition effect of GSN on the proliferation of 786-0 ccRCC cells
To investigate the effect of GSN on 786-0 cell proliferation, the cell viability of the transfected and non-transfected 786-0 cells was measured at 0, 12, 24, 36, 48, 60 and 72 h using the MTT method. As shown in Fig. 4 and Table I, the OD value of the 786-0/GSN cells was significantly lower than that of the 786-0/GFP and 786-0 cells following culture for 24 h (P<0.05), and the difference was more apparent following a longer culture period (P<0.001 for 36–72 h). No statistical differences were observed at the various time points between the 786-0/GFP and 786-0 groups (P>0.05). These results indicate that GSN may inhibit the proliferation of 786-0 cells in vitro.
Table IOptical density values of the three groups of 786-0 clear cell renal cell carcinoma cells following culture for 0, 12, 24, 36, 48, 60 and 72 h (mean ± standard deviation). |
Inhibition effect of GSN on the adhesion of 786-0 ccRCC cells
The effect of GSN on the adhesion ability of 786-0 cells was also examined using the MTT method. As shown in Fig. 5, the OD value of the 786-0/GSN cells (1.2600±0.02646) was decreased when compared with the 786-0/GFP and 786-0 cells (7.2533±0.04041 and 7.3000±0.02646, respectively). The difference between the 786-0/GSN group and the other two groups (t=214.902; P<0.0001 and t=279.598; P<0.0001 compared with the 786-0/GFP and 786-0 groups, respectively). was identified to be significant; however, no statistical difference was observed in the OD value between the 786-0/GFP group and the 786-0 group (t=1.673; P=0.181). The result revealed that the extent of 786-0/GSN cell adherence to the culture plates was markedly lower than that of the 786-0/GFP and 786-0 groups.
Effect of GSN on the invasion ability of 786-0 ccRCC cells
The effect of GSN on the invasion ability of 786-0 cells was observed by penetration experiments using Transwell chambers coated in Matrigel. The cells that possess invasion ability digest Matrigel and are able to penetrate the 8-µm pores on the polycarbonate membrane. In the present study, fewer cells were observed to penetrate the Matrigel in the 786-0/GSN group, as compared with the cells of the 786-0/GFP and 786-0 groups (Fig. 6). The average penetration rate of the 786-0/GSN cells (6.8000±0.83666) was significantly lower than that of the 786-0/GFP (19.2000±4.32435) and 786-0 (19.0000±4.35890) cells (t=6.295, P<0.0001; t=6.146, P<0.0001). No statistical difference was identified in average penetration rate between the 786-0/GFP and 786-0 groups (t=0.073; P=0.944).
Effect of GSN on the expression levels of MMP2, MMP9 and E-cadherin
The expression levels of MMP2 and MMP9 were detected in the transfected and non-transfected 786-0 cells using the ELISA method. As shown in Fig. 7, the expression levels of MMP2 and MMP9 were significantly decreased in the 786-0/GSN cells, and the OD value of MMP2 and MMP9 in the 786-0/GSN cells (1.0400±0.03606 and 3.6067±0.07506, respectively) was lower than that of the 786-0/GFP (2.6633±0.08327 and 5.8633±0.03055, respectively) and 786-0 cells (2.7667±0.01528 and 5.9133±0.04509, respectively) following 48 h of transfection, with a significant difference between the 786-0/GSN and 786-0/GFP cells (t=30.987, P<0.0001; t=48.234, P<0.0001) and between the 786-0/GSN and 786-0 cells (t=76.375, P<0.0001; t=45.629, P<0.0001). No statistical difference was noted between the 786-0/GFP and 786-0 cells (t=2.114, P=0.161; t=1.590, P=0.197).
To further elucidate the effect of GSN on the expression levels of MMP2 and MMP9, the expression level of the two proteins was assessed by western blot analysis. E-cadherin was also analyzed. It was identified that in the 786-0/GSN cells, the expression levels of MMP2 and MMP9 were markedly decreased, while the expression level of E-cadherin was markedly increased (Fig. 7). Significant differences were observed between the 786-0/GSN group and the other two groups [786-0/GSN vs. 786-0/GFP: t=14.981 (P<0.001) for MMP2; t=9.052 (P<0.001) for MMP9; and t=12.645 (P<0.001) for E-cadherin; 786-0/GSN vs. 786-0: t=30.654 (P<0.001) for MMP2; t=9.749 (P<0.001) for MMP9; and t=8.338 (P<0.001) for E-cadherin]. No statistically significant difference was observed between the 786-0/GFP and 786-0 groups [t=2.115 (P=0.102) for MMP2; t=2.396 (P=0.075) for MMP9; and t=0.251 (P=0.814) for E-cadherin].
Discussion
RCC is the most common neoplasm of the adult kidney and the most prevalent type of kidney tumor is the ccRCC subtype (4). However, the exact molecular mechanism of ccRCC remains to be elucidated. The treatment of metastatic ccRCC continues to be a challenge for clinicians and causes ~35% of RCC-associated mortalities (12). The majority of RCC patients already exhibit either metastatic disease at the initial diagnosis or distant metastases following primary tumor resection (13). Since advanced ccRCC is highly resistant to chemotherapy and cytotoxic drugs, following tumor resection a third of the patients will have a recurrence. Furthermore, a quarter of the patients present locally invasive or metastatic RCC (7). This therefore led to the speculation that the prognosis of ccRCC is poor partly due to the fact that certain factors correlate with its proliferation and invasion. In recent years, particular focus has been placed on actin-binding proteins and their participation in the migratory process of cancer cells. Therefore, in the present study, GSN was selected as a novel biological marker to investigate its role in the proliferation and invasion of ccRCC.
The effect of GSN on the proliferation of 786-0 ccRCC cells was observed. An MTT assay revealed that the OD value of 786-0/GSN cells was markedly lower than that of 786-0/GFP and 786-0 cells after being cultured for 24 h, and the difference was more apparent with a longer culture duration. The result indicates that GSN inhibits the proliferation of 786-0 ccRCC cells. GSN is a Ca2+-activated actin-binding protein that severs F-actin filaments by breaking non-covalent bonds between the actin monomers in a polymer. It results in high-affinity complexes of GSN, which remain bound to the barbed ends of filaments, thus inhibiting extension ('capped' filaments) (14). On reduction of free intracellular Ca2+ levels, and in the presence of polyphosphoinositides, GSN is released from the barbed ends to provide sites for rapid actin filament extension. GSN is the most potent actin filament-severing protein that has been identified to date (9). The data from the present study implied that overexpression of GSN may inhibit the proliferation of 786-0 ccRCC cells. To the best of our knowledge, there are only a small number of relevant studies on the association between GSN and ccRCC, therefore, the specific pathogenesis requires further investigation.
The effect of GSN on the adhesion ability of 786-0 ccRCC cells was examined using the MTT method. The OD value of the 786-0/GSN cells was observed to be significantly decreased when compared with the 786-0/GFP and 786-0 cells. This indicated that GSN inhibits the adhesion ability of 786-0 cells. A previous study proposed that actin capping, nucleation and severing are important functions of GSN, which are required for regulation of adhesion maturation and collagen matrix remodeling. The study demonstrated that minor inhibition of the severing function of GSN, by binding to non-muscle myosin IIA, may be necessary initially to prevent actin depolymerization in the locale of adhesions (15). In addition, Ke et al (16) identified that B cell lymphoma-2 (BCL2) forms a complex with actin and GSN to decrease GSN-severing activity and increase actin polymerization, which suppresses the cell adhesion processes. The association between increased BCL2, and actin polymerization and suppression of cell adhesion was a novel observation that may provide a plausible explanation to elucidate whether BCL2 overexpression in certain tumors is correlated with improved patient survival (16). However, a fundamental characteristic of malignant and transformed cells is the aberrant organization of the actin cytoskeleton, resulting from the associated disruption of the cytoskeleton (9). This may lead to the inhibitory action of GSN overexpression on the adhesions of 786-0 cells, however, the exact mechanisms have not been clearly elucidated.
The effect of GSN on the invasion ability of 786-0 cells was evaluated using penetration experiments with Transwell chambers coated in Matrigel. Fewer cells had penetrated the Matrigel in the 786-0/GSN group, when compared with the cells of the 786-0/GFP and 786-0 groups. The average penetration rate of the 786-0/GSN cells was lower than that of the 786-0/GFP and 786-0 cells. The result indicates that over-expression of GSN may inhibit the invasion of 786-0 ccRCC cells. These findings contrast with those of existing studies. Zhuo et al (17) revealed novel functions of GSN in colorectal tumor cells, where invasion was promoted via modulation of the urokinase-type plasminogen activator cascade, with GSN potentially exerting a significant role in colorectal tumor dissemination to metastatic sites. The results of Zhuo et al (17) may be marginally attributable to the actin depolymerizing effect of GSN. However, a recent study demonstrated that the nuclear import of GSN-like actin-capping protein, as another GSN family member, and GSN had been identified to be significant in non-small cell lung cancer invasion and metastasis (18). Furthermore, De Corte et al (19) revealed that invasion induced by GSN was dependent on Ras activity, acting through the PI3K-Rac signaling pathway via the Ras guanine nucleotide exchange factor, Sos-1. These findings established a connection between GSN and the Ras oncogenic signaling pathway (19).
In order to investigate the mechanisms of GSN inhibiting the invasion of 786-0 ccRCC cells, the expression levels of MMP2, MMP9 and E-cadherin were detected in the current study. ELISA and western blot analysis revealed that GSN downregulated the expression levels of MMP2 and MMP9 in the 786-0 cells, which was consistent with previous studies (20,21). Numerous molecules are involved in tumor invasion, including MMPs. MMPs are a family of related enzymes that degrade the extracellular matrix (ECM). The activation of these enzymes enables tumor cells to access the vasculature, invade target organs and develop into tumor metastases. Previous studies have indicated that full length plasma GSN is a known substrate for the MMPs, and is cleaved most efficiently by MMP3, followed by MMP2 and MMP9. Three sites that are cleaved by MMP2 and MMP9 in full length plasma GSN were identified and all were in unstructured regions (22). A recent study observed that furin cleavage of full length D187N GSN cleaved an internal β-strand in the G2 domains, which may lead to unfolding of the G2 domains that are particularly susceptible to cleavage by proteases, including the MMPs in the ECM (8). Although MMP2 and MMP9 were associated with the structure of GSN, the mechanisms of downregulating the expression levels of MMP2 and MMP9 in 786-0 ccRCC cells were not elucidated in the current study. The expression level of E-cadherin was also analyzed by western blotting in the present study; conversely, it was identified that GSN upregulated the expression of E-cadherin. The E-cadherin gene is a tumor suppressing gene that expresses the E-cadherin transmembrane glycoprotein, which plays a significant role in adhesion and differentiation of epithelial cells; an important protective mechanism against neoplasm formation (23). Rao et al (24) reported that alterations in the expression levels of the cytoskeletal proteins, GSN and E-cadherin, had been implicated in urothelial carcinoma tumorigenesis. Furthermore, GSN and E-cadherin possess distinctive expression patterns. GSN, but not E-cadherin, provided independent prognostic information for high-grade urothelial carcinomas. However, the mechanism underlying how the altered expression levels were associated with tumor progression was unclear. Therefore, it was hypothesized in the present study that the upregulation of E-cadherin is closely associated with GSN, so as to inhibit invasion of 786-0 ccRCC cells; although the exact pathogenesis remains unclear.
In conclusion, GSN was examined in vitro, and was observed to inhibit the proliferation and invasion of 786-0 ccRCC cells. These findings contribute to the existing knowledge on the biological functions of GSN and its effects on ccRCC. Numerous in vivo experiments on the impact of GSN in patients with ccRCC were not included in the results of the present study, which may be considered as a limitation of the study. Future investigations are required in order that more clinical samples may be collected, and the proliferation and invasion of ccRCC may be investigated in more depth. These findings may demonstrate whether GSN could serve as a novel molecular target for the development of effective therapeutic strategies to prevent the metastasis of kidney carcinoma and, therefore, improve the survival rates of patients with ccRCC.
Acknowledgments
The authors would like to thank Dr Xiaoling Zhu, Professor Limin Cai, Professor Qinggang Meng and Professor Xiaoming Jin who participated in this study, as well as their colleagues for their cooperation. The authors would also like to thank the laboratory of Wei Si Teng Company (Chongqing, China; www.cqwestern.com) for assisting with the research.
Abbreviations:
GFP |
green fluorescent protein |
GSN |
gelsolin |
MTT |
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide |
References
Bastola P, Stratton Y, Kellner E, Mikhaylova O, Yi Y, Sartor MA, Medvedovic M, Biesiada J, Meller J and Czyzyk-Krzeska MF: Folliculin contributes to VHL tumor suppressing activity in renal cancer through regulation of autophagy. PLoS One. 8:e700302013. View Article : Google Scholar : PubMed/NCBI | |
Chow WH, Dong LM and Devesa SS: Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 7:245–257. 2010. View Article : Google Scholar : PubMed/NCBI | |
Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar | |
Kovacs G, Akhtar M, Beckwith BJ, Bugert P, Cooper CS, Delahunt B, Eble JN, Fleming S, Ljungberg B, Medeiros LJ, et al: The Heidelberg classification of renal cell tumours. J Pathol. 183:131–133. 1997. View Article : Google Scholar : PubMed/NCBI | |
Ramakrishnan S, Ellis L and Pili R: Histone modifications: Implications in renal cell carcinoma. Epigenomics. 5:453–462. 2013. View Article : Google Scholar : PubMed/NCBI | |
Kim HL, Seligson D, Liu X, Janzen N, Bui MH, Yu H, Shi T, Figlin RA, Horvath S and Belldegrun AS: Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res. 10:5464–5471. 2004. View Article : Google Scholar : PubMed/NCBI | |
Chuang MJ, Sun KH, Tang SJ, Deng MW, Wu YH, Sung JS, Cha TL and Sun GH: Tumor-derived tumor necrosis factor-alpha promotes progression and epithelial-mesenchymal transition in renal cell carcinoma cells. Cancer Sci. 99:905–913. 2008. View Article : Google Scholar : PubMed/NCBI | |
Solomon JP, Page LJ, Balch WE and Kelly JW: Gelsolin amyloidosis: Genetics biochemistry pathology and possible strategies for therapeutic intervention. Crit Rev Biochem Mol Biol. 47:282–296. 2012. View Article : Google Scholar : PubMed/NCBI | |
Li GH, Arora PD, Chen Y, McCulloch CA and Liu P: Multifunctional roles of gelsolin in health and diseases. Med Res Rev. 32:999–1025. 2012. View Article : Google Scholar : PubMed/NCBI | |
Baig RM, Mahjabeen I, Sabir M, Masood N, Ali K, Malik FA and Kayani MA: Mutational spectrum of gelsolin and its down regulation is associated with breast cancer. Dis Markers. 34:71–80. 2013. View Article : Google Scholar : PubMed/NCBI | |
Visapää H, Bui M, Huang Y, Seligson D, Tsai H, Pantuck A, Figlin R, Rao JY, Belldegrun A, Horvath S and Palotie A: Correlation of Ki-67 and gelsolin expression to clinical outcome in renal clear cell carcinoma. Urology. 61:845–850. 2003. View Article : Google Scholar : PubMed/NCBI | |
Siegel R, Naishadham D and Jemal A: Cancer statistics 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI | |
Finley DS, Pantuck AJ and Belldegrun AS: Tumor biology and prognostic factors in renal cell carcinoma. Oncologist. 16(Suppl 2): S4–S13. 2011. View Article : Google Scholar | |
Nag S, Larsson M, Robinson RC and Burtnick LD: Gelsolin: The tail of a molecular gymnast. Cytoskeleton (Hoboken). 70:360–384. 2013. View Article : Google Scholar | |
Arora PD, Wang Y, Bresnick A, Dawson J, Janmey PA and McCulloch CA: Collagen remodeling by phagocytosis is determined by collagen substrate topology and calcium-dependent interactions of gelsolin with nonmuscle myosin IIA in cell adhesions. Mol Biol Cell. 24:734–747. 2013. View Article : Google Scholar : PubMed/NCBI | |
Ke H, Zhang JY, Akiyama SK and French JE: BCL2 interaction with actin in vitro may inhibit cell motility by enhancing actin polymerization. Cell Adh Migr. 5:6–10. 2011. View Article : Google Scholar : | |
Zhuo J, Tan EH, Yan B, Tochhawng L, Jayapal M, Koh S, Tay HK, Maciver SK, Hooi SC, Salto-Tellez M, et al: Gelsolin induces colorectal tumor cell invasion via modulation of the urokinase-type plasminogen activator cascade. PloS One. 7:e435942012. View Article : Google Scholar : PubMed/NCBI | |
Zhu WY, Hunag YY, Liu XG, He JY, Chen DD, Zeng F, Zhou JH and Zhang YK: Prognostic evaluation of CapG gelsolin P-gp GSTP1 and Topo-II proteins in non-small cell lung cancer. Anat Rec (Hoboken). 295:208–214. 2012. View Article : Google Scholar | |
De Corte V, Bruyneel E, Boucherie C, Mareel M, Vandekerckhove J and Gettemans J: Gelsolin-induced epithelial cell invasion is dependent on ras-rac signaling. EMBO J. 21:6781–6790. 2002. View Article : Google Scholar : PubMed/NCBI | |
Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, Hsu CY, Tsai MH, Lai CH and Lin KH: Overexpression of gelsolin in human cervical carcinoma and its clinicopathological significance. Gynecol Oncol. 120:135–144. 2011. View Article : Google Scholar | |
Zhan L, Zhang H, Zhang Q, Woods CG, Chen Y, Xue P, Dong J, Tokar EJ, Xu Y, Hou Y, et al: Regulatory role of KEAP1 and NRF2 in PPARγ expression and chemoresistance in human non-small-cell lung carcinoma cells. Free Radic Biol Med. 53:758–768. 2012. View Article : Google Scholar : PubMed/NCBI | |
Park SM, Hwang IK, Kim SY, Lee SJ, Park KS and Lee ST: Characterization of plasma gelsolin as a substrate for matrix metalloproteinases. Proteomics. 6:1192–1199. 2006. View Article : Google Scholar : PubMed/NCBI | |
Anbiaee R, Mojir Sheibani K, Torbati P and Jaam H: Abnormal expression of e-cadherin in gastric adenocarcinoma and its correlation with tumor histopathology and helicobacter pylori infection. Iran Red Crescent Med J. 15:218–222. 2013. View Article : Google Scholar : PubMed/NCBI | |
Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A and Palotie A: Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma. Cancer. 95:1247–1257. 2002. View Article : Google Scholar : PubMed/NCBI |